Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masashi Namba

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 12, 2021
[An Autopsy Case of IGF‒Ⅱ Secreting Gastric Cancer with Non‒Islet Cell Tumor Hypoglycemia]Taro Ueda, Masashi Namba, Tadashi Senoo, et al.
Internal Medicine (Tokyo, Japan)|October 13, 2017
Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with LymphangioleiomyomatosisMasashi Namba, Takeshi Masuda, Takashi Nakamura, et al.
Pacing and Clinical Electrophysiology : PACE|June 16, 2005
Prevalence and clinical course of the juveniles with Brugada-type ECG in Japanese populationHiroki Oe, Masahiko Takagi, Atsushi Tanaka, et al.
Stem Cell Research & Therapy|August 24, 2021
Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activityHiroshi Takahashi, Taku Nakashima, Takeshi Masuda, et al.
Respiratory Medicine|April 1, 2023
Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseasesTaku Nakashima, Keitaro Omori, Masashi Namba, et al.
BMJ Open Respiratory Research|February 20, 2024
High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosisShinichiro Miura, Hiroshi Iwamoto, Masashi Namba, et al.
Cancer Letters|November 4, 2018
Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1Masashi Namba, Noboru Hattori, Hironobu Hamada, et al.
Journal of Cellular and Molecular Medicine|February 9, 2019
Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblastsTakeshi Masuda, Taku Nakashima, Masashi Namba, et al.
Stem Cell Research & Therapy|September 17, 2021
Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosisShun Takao, Taku Nakashima, Takeshi Masuda, et al.
Cancers|February 25, 2023
Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal TransitionKentaro Tokumo, Takeshi Masuda, Taku Nakashima, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 12, 2021
[An Autopsy Case of IGF‒Ⅱ Secreting Gastric Cancer with Non‒Islet Cell Tumor Hypoglycemia]Taro Ueda, Masashi Namba, Tadashi Senoo, et al.
Internal Medicine (Tokyo, Japan)|October 13, 2017
Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with LymphangioleiomyomatosisMasashi Namba, Takeshi Masuda, Takashi Nakamura, et al.
Pacing and Clinical Electrophysiology : PACE|June 16, 2005
Prevalence and clinical course of the juveniles with Brugada-type ECG in Japanese populationHiroki Oe, Masahiko Takagi, Atsushi Tanaka, et al.
Stem Cell Research & Therapy|August 24, 2021
Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activityHiroshi Takahashi, Taku Nakashima, Takeshi Masuda, et al.
Respiratory Medicine|April 1, 2023
Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseasesTaku Nakashima, Keitaro Omori, Masashi Namba, et al.
BMJ Open Respiratory Research|February 20, 2024
High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosisShinichiro Miura, Hiroshi Iwamoto, Masashi Namba, et al.
Cancer Letters|November 4, 2018
Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1Masashi Namba, Noboru Hattori, Hironobu Hamada, et al.
Journal of Cellular and Molecular Medicine|February 9, 2019
Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblastsTakeshi Masuda, Taku Nakashima, Masashi Namba, et al.
Stem Cell Research & Therapy|September 17, 2021
Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosisShun Takao, Taku Nakashima, Takeshi Masuda, et al.
Cancers|February 25, 2023
Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal TransitionKentaro Tokumo, Takeshi Masuda, Taku Nakashima, et al.
Pageof 3